• Northstrive Biosciences and Yuva Biosciences previously announced the AI Development Program, a collaboration leveraging MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.
• Phase II of this collaboration involved YuvaBio compiling a selection of small molecule candidates with the potential of promoting mitochondrial health to combat obesity and cardiac diseases.

 Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc.  announced the completion of Phase II of the AI Development Program (“Phase II”) with strategic partner Yuva Biosciences, Inc. (“YuvaBio”). As part of the Phase II objective, YuvaBio delivered to Northstrive a shortlist of small molecule candidates YuvaBio believes has the potential to promote mitochondrial health to combat obesity and cardiac diseases.

YuvaBio completed Phase II by compiling a targeted collection of compounds drawn from 12 curated libraries. These libraries were designed to include molecules with activity across key disease areas—obesity, cardiometabolic disorders, and lipid & glucose metabolism—thereby aligning closely with Northstrive Bio’s therapeutic focus. MitoNova™, YuvaBio’s AI platform, screened the aggregated chemical space to evaluate predicted impact on a specified target involved in muscle preservation and metabolic health. YuvaBio presented Northstrive with a shortlist of compounds ready for biological validation in vitro. Northstrive has the opportunity to review the list of compounds and analyze their potential to be advanced to experimental testing and clinical development.